EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY 4.0

A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer’s disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial

David S Henry iD, Richard G Pellegrino iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0292863 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift PLOS ONE, 2023. Verfasst von David S Henry und 1 weiteren Autor:innen. Beteiligte Einrichtung: Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States of America. Hauptthemen laut MEDLINE: Alzheimer Disease, Hypertension, Pulmonary. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phosphodiesterase-5 inhibitors (PDE5i) have been evaluated as a novel treatment for Alzheimer’s disease and related dementias (ADRD), but two recent cohort studies have offered opposing conclusions.

Methods

We performed an unmatched case-control study using electronic medical records from a large healthcare system to evaluate the association of PDE5i use and ADRD in patients ≥65 years old.

Results

Odds of PDE5i exposure were 64.2%, 55.7%, and 54.0% lower in patients with ADRD than controls among populations with erectile dysfunction, benign prostatic hyperplasia, and pulmonary hypertension, respectively. We observed odds ratios less than unity among males and females and with exposure to the PDE5i sildenafil (Viagra®) and tadalafil (Cialis®). We also evaluated the odds of exposure to two other common treatments for pulmonary hypertension: endothelin receptor antagonists (ERA) and calcium channel blockers (CCB). The odds of ERA exposure were 63.2% lower, but the odds of CCB exposure were 30.7% higher, in patients with ADRD than controls among the population with pulmonary hypertension.

Conclusions

Our results reconcile the opposing conclusions from the previous observational studies and support further research into using PDE5i for prevention and treatment of ADRD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHypertension, PulmonaryAgedFemaleHumansMaleCase-Control StudiesCyclic Nucleotide Phosphodiesterases, Type 5Endothelin Receptor AntagonistsPhosphodiesterase 5 InhibitorsSildenafil CitrateTadalafil

Substanzen

Cyclic Nucleotide Phosphodiesterases, Type 5Endothelin Receptor AntagonistsPhosphodiesterase 5 InhibitorsSildenafil CitrateTadalafil

Autor:innen und Institutionen

  • Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States of America.

ORCID-Profile: David S Henry, Richard G Pellegrino

Zitieren

APA

Henry, D. S., & Pellegrino, R. G. (2023). A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer’s disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0292863

Vancouver

Henry DS, Pellegrino RG. A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer’s disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial. PLOS ONE. 2023. doi:10.1371/journal.pone.0292863

BibTeX
@article{Henry2023,
  author = {Henry, David S and Pellegrino, Richard G},
  title = {A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer’s disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0292863}
}
Kostenlos starten →